Here’s a translation.
The Study

The study focused on multiple myeloma, a type of blood cancer. Patients with relapsed or refractory multiple myeloma (meaning their disease came back or didn't respond to previous treatments) were involved.
Researchers wanted to compare two treatment options:
BVd: Belantamab mafodotin (also known as Blenrep), bortezomib (Velcade), and dexamethasone
DVd: Daratumumab (Darzalex), bortezomib, and dexamethasone
Key Results

PFS (Progression-Free Survival):
Patients on BVd went significantly longer without their cancer worsening – on average, 36.6 months.
Patients on DVd had disease progression much sooner – on average, 13.4 months.
OS (Overall Survival):
While not fully conclusive, early signals suggest patients on BVd might live longer. Further research is needed to confirm this.
ORR (Overall Response Rate):
More patients on BVd showed signs of their cancer improving: 82.7% compared to 71.3% on DVd.
DOR (Duration of Response):
The positive responses from BVd lasted twice as long as DVd: 35.6 months vs. 17.8 months.
Side Effects

AE (Adverse Event): All patients had at least one side effect, which is common with cancer treatments.
Grade 3/4 TRAE (Treatment-Related Adverse Event): BVd caused more severe side effects (in 90% of patients) compared to DVd (67%).
SAE (Serious Adverse Event): These were more frequent with BVd (50% of patients) vs DVd (37%).
Ocular AEs: Specifically, eye-related side effects were much more common with BVd (79%) than DVd (29%). These eye problems would need careful management.
In Plain English

For controlling relapsed or refractory multiple myeloma, the combination of belantamab mafodotin, bortezomib, and dexamethasone (BVd) appears significantly more effective than the combination of daratumumab, bortezomib, and dexamethasone (DVd).
Patients on BVd experience their disease staying under control much longer, have stronger reactions to the treatment, and the benefits of the treatment last longer.
However, BVd comes with a higher risk of more severe side effects, especially problems with vision.
Important Considerations

The potential advantage of longer overall survival with BVd needs further study.
It's crucial to weigh the significantly better disease control BVd offers against the increased severity of side effects. Doctors and patients would need to discuss these on an individual basis to make the best treatment decision.

Yes, lots of side effects. With 3 drug combinations it would be hard to tell what's causing what.

Thank you @A MyMyelomaTeam Member

Mentioned Users

A MyMyelo...

Quality of life is the most important aspect to consider in my opinion. I watched my mom suffer through ovarian cancer treatments. When it came back for the 3rd time she had surgery to remove a tumor blocking the colon, but decided against chemo, and chose quality of life. Amazingly, she lived for another 4 years, and they were quality years. I didn’t see in the study what types of MM they treated. I have IgA Kappa with deletions, additions and translocations. They would never choose me, but I thought the information was worth sharing.
Paula 🌹

There seems to be a lot of side effects. I guess what matters is whether it's worth it to the person who decides.